pailbeast3
About
Nine-Year Mean Follow-up involving Ccardiotoxicity as well as Efficacy associated with Trastuzumab Concurrently Using Anthracycline-Based as well as Anthracycline-Free Neoadjuvant Chemo in HER2-Positive Breast Cancer Patients.
Nine-Year Mean Follow-up involving Ccardiotoxicity as well as Efficacy associated with Trastuzumab Concurrently Using Anthracycline-Based as well as Anthracycline-Free Neoadjuvant Chemo in HER2-Positive Breast Cancer Patients.